Articles amb requisits d'accés públic - Vincenzo BagnardiMés informació
No estan disponibles en cap lloc: 20
Revisa
Pattern of declining hemoglobin concentration before cancer diagnosis
G Edgren, V Bagnardi, R Bellocco, H Hjalgrim, K Rostgaard, M Melbye, ...
International journal of cancer 127 (6), 1429-1436, 2010
Requisits: US National Institutes of Health
Revisa
Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk)
A Mazzanti, A Trancuccio, D Kukavica, E Pagan, M Wang, M Mohsin, ...
EP Europace 24 (4), 614-619, 2022
Requisits: Government of Italy
Revisa
Metaplastic breast cancer: prognostic and therapeutic considerations
G Corso, S Frassoni, A Girardi, E De Camilli, E Montagna, M Intra, ...
Journal of Surgical Oncology 123 (1), 61-70, 2021
Requisits: Government of Italy
Revisa
Contralateral axillary lymph node metastases from breast carcinoma: is it time to review TNM cancer staging?
F Magnoni, M Colleoni, D Mattar, G Corso, V Bagnardi, S Frassoni, ...
Annals of surgical oncology 27, 4488-4499, 2020
Requisits: Government of Italy
Revisa
Modelling body mass index and endometrial cancer risk in a pooled‐analysis of three case–control studies
M Rota, F Rumi, V Bagnardi, L Dal Maso, A Zucchetto, F Levi, ...
BJOG: An International Journal of Obstetrics & Gynaecology 123 (2), 285-292, 2016
Requisits: Government of Italy
Revisa
A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 …
S Luzzago, O de Cobelli, G Cozzi, G Peveri, V Bagnardi, M Catellani, ...
BJU international 126 (1), 104-113, 2020
Requisits: Government of Italy
Revisa
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral …
G Curigliano, V Bagnardi, F Bertolini, M Alcalay, MA Locatelli, L Fumagalli, ...
The Breast 24 (3), 263-271, 2015
Requisits: Government of Italy
Revisa
CDH1 germline mutations in healthy individuals from families with the hereditary diffuse gastric cancer syndrome
G Corso, F Magnoni, G Massari, CM Trovato, AM De Scalzi, E Vicini, ...
Journal of Medical Genetics 59 (4), 313-317, 2022
Requisits: Government of Italy
Revisa
Ten-year results of hypofractionated whole breast radiotherapy and intraoperative electron boost in premenopausal women
MC Leonardi, CF Cormio, S Frassoni, S Dicuonzo, C Fodor, M Intra, ...
Radiotherapy and Oncology 177, 71-80, 2022
Requisits: Government of Italy, AIRC Foundation for Cancer Research in Italy
Revisa
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations
G Corso, F Magnoni, V Nicastro, V Bagnardi, CM Trovato, P Veronesi
Seminars in Oncology 49 (2), 130-135, 2022
Requisits: Government of Italy
Revisa
Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience
M Augugliaro, G Marvaso, R Cambria, M Pepa, V Bagnardi, S Frassoni, ...
Physica Medica 92, 62-68, 2021
Requisits: Government of Italy
Revisa
Implant risk failure in patients undergoing postmastectomy 3-week hypofractionated radiotherapy after immediate reconstruction
DP Rojas, MC Leonardi, S Frassoni, A Morra, MA Gerardi, E La Rocca, ...
Radiotherapy and Oncology 163, 105-113, 2021
Requisits: Government of Italy
Revisa
Small-size (40 µm) beads loaded with irinotecan in the treatment of patients with colorectal liver metastases
G Mauri, D Rossi, S Frassoni, G Bonomo, N Camisassi, P Della Vigna, ...
CardioVascular and Interventional Radiology 45 (6), 770-779, 2022
Requisits: Government of Italy
Revisa
Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment—Authors' reply
A Mazzanti, A Trancuccio, D Kukavica, E Pagan, M Wang, M Mohsin, ...
EP Europace 24 (4), 698-699, 2022
Requisits: Government of Italy
Revisa
Does failed mapping predict sentinel lymph node metastasis in cN0 breast cancer?
F Magnoni, G Corso, L Gilardi, E Pagan, G Massari, A Girardi, F Ghidinelli, ...
Future Oncology 18 (2), 193-204, 2022
Requisits: Government of Italy
Revisa
Ten‐year outcome results of cT4 breast cancer after neoadjuvant treatment
G Corso, S Kahler‐Ribeiro‐Fontana, E Pagan, V Bagnardi, F Magnoni, ...
Journal of Surgical Oncology 124 (8), 1242-1250, 2021
Requisits: Government of Italy
Revisa
Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology
D Mattar, A Di Filippo, A Invento, D Radice, M Burcuta, V Bagnardi, ...
European Journal of Surgical Oncology 47 (10), 2499-2505, 2021
Requisits: Government of Italy
Revisa
Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: Prospective series of 287 early breast cancer patients
S Dicuonzo, MC Leonardi, S Raimondi, G Corrao, V Bagnardi, ...
Clinical and Translational Oncology 23, 1415-1428, 2021
Requisits: Government of Italy
Revisa
Comparing TomoHelical and TomoDirect in postmastectomy hypofractionated radiotherapy after immediate breast reconstruction
S Dicuonzo, F Patti, R Luraschi, S Frassoni, DP Rojas, M Zaffaroni, ...
Physica Medica 90, 66-72, 2021
Requisits: Government of Italy, AIRC Foundation for Cancer Research in Italy
Revisa
Intra-inter-observer repeatability in liver computed tomography volumetry in patients undergoing radioembolization simulation
A Masperi, V Cubadda, L Bombelli, R Labruna, V Bagnardi, CI Fodor, ...
Abdominal Radiology 46, 3448-3455, 2021
Requisits: Government of Italy
Les dades de publicació i de finançament es determinen automàticament per mitjà d'un programa informàtic